复星医药复方聚乙二醇电解质散药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating progress in the company's product pipeline for treating chronic constipation [1] Group 1 - The drug is classified as a chemical medication intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]